The Boston-based nonprofit T1D Exchange has been posing a Question of the Day to thousands of people living with type 1 diabetes (T1D) for nearly 10 years now. Questions run the gamut from How do you [dose insulin] for pizza? to Do you own a breath keytone meter? to Do you expect to take a device vacation for at least a few days this summer?
What a treasure trove of information the T1D Exchange must have amassed by now!
On first glance, this Question of the Day program looks to be a seamless and effective way for people who care about diabetes to ponder questions, share answers, see statistics, and interact with other like-minded folks all worthy and valuable functions.
But if you take a deeper dive into the T1D Exchange and this nearly decade-year old program, youll find much more than that.
The questions, answers, and much of the community that takes part in it constitute a living, breathing, thinking, and sharing database, helping not just one another, but to drive research to improve the lives of those with T1D across the board.
David Panzirer, trustee of The Leona M. and Harry B. Helmsley Charitable Trust funders of the T1D Exchange explained that those were their exact hopes for the Question of the Day program when it launched a decade ago. He worked on it with Dana Ball, program director of the T1D Program at the Helmsley Trust and former executive director of the Iacocca Foundation.
The real impetus was [when we looked around the diabetes research landscape] and thought, wheres the data? Panzirer told DiabetesMine.
The truth is, it did not exist in places most could access. It was off in vaulted places that no one else was willing to share, he said.
That meant researchers working on diabetes theories and treatments often had to add months, or even years, to their research timeline while they hunted down needed data. This contributed to why progress in the diabetes landscape seemed to come at a crawl, he said.
Today, the T1D Exchange, through both those Questions of the Day and their patient Registry that sprouted from that, now has treatment data and lifestyle information of about 30,000 people with diabetes. Of those, about 15,000 have opted to be part of their Registry, which seeks annual medical and other data and often asks members to participate in studies.
The T1D Exchange data culled from both of those sources has been presented in studies and programs around the world and continues to inform researchers, product manufacturers, and more on what the diabetes community needs.
All that data exists in one easy-to-access place, and is helping, many say, to speed up the process of research and bring new deliverables to market. Otherwise known as: improving the lives of people with diabetes.
And while doing all that heavy lifting, it also still continues to provide people with diabetes and those who care about them a place to chat, learn, vent, and adapt.
We use it as a platform to engage but also to share, T1D Exchange CEO David Walton told DiabetesMine. Its a great way to get [a large group of people] to respond.
Questions of the Day come from a variety of sources. The T1D Exchange team holds monthly brainstorming sessions, Walton said, to hone in on both what they may be wondering, what has bubbled up in the community at large, what companies and researchers may be curious about, and some staples, like the quarterly What is your A1C? question.
Anyone can opt in to respond, and much of the conversation, including tip sharing and support, happens online as each question is released.
That, Walton said, is where the support and sharing they know the community appreciates takes place.
Panzirer said it took them a solid 2 years and $20 million to get to the point of being a strong data collection program. From there, they both made that data accessible to researchers and other stakeholders and used it to begin what they really hoped to do: Push for faster, smarter and more impactful research and breakthroughs.
Their first step came when theyd only gathered about 10 percent of the group of respondents they have now.
With data from about 4,000 people, he said, they went before the Food and Drug Administration (FDA) and showed them two things: that the average A1C among their base was at 8.4 percent, and that 10 percent of the participants had experienced a severe diabetes event [blood sugar either low or high enough to require assistance, hospitalization, or both] in the past year.
I can tell you, their jaws were on the floor, Panzirer remembered of the FDA team. They had no idea. Now, we had clinical proof that the perception many had that insulin works fine and people with diabetes can easily do well with it wasnt a reality.
Without a doubt, he said, we were able to open their eyes and shine a light. It shined a light on just how poorly people were doing. We had the data to prove it.
To illustrate how this can culminate in helping people in real life and pushing research and industry to create life-bettering deliverables, Panzirer points to the success of Locemia Solutions.
Robert Oringer, an innovative businessman and the father of two sons with T1D, had an idea: What if emergency glucagon could be easier in every way: to carry, to administer, to store and more? After all, as the father of two sons with T1D, he knew well how bulky, stressful, confusing and even frightening the classic red case emergency glucagon rescue kits could feel.
He approached the T1D Exchange, who asked their community via Questions of the Day all about their feelings around rescue glucagon to confirm what Oringer saw. They jumped on board gathering data.
With that data and confidence in his product, they formed a committee of key opinion leaders like leading diabetes educator and author Hope Warshaw and well-known Yale endocrinologist Dr. William Tamborlane, and then went on to run clinical trials.
That data and study result information gave Locemia the platform to reach out to bigger names. Soon, the pharma giant Eli Lilly and Company took over the project.
Today, the product they created, the first-ever nasal glucagon Baqsimi, is available on the market, making carrying and using emergency glucagon a tremendously simpler, less stressful and more palatable option.
In other words, the data improved lives.
The timing of their first FDA meeting lines up, too, with the period of time when the FDA agreed to streamline the review process for continuous glucose monitors and after that, smarter insulin pumps and hybrid closed loop systems.
Today, just a decade past all of that seeming like a pipedream, new products are coming faster and faster.
The data that so many can access, Panzirer said, is a key reason why.
We forced a whole field to accelerate faster, he said. We forced the competition, and thats fueling more and more improvements.
While all this is going on, the questions continue to offer moral and educational support to thousands on a near daily basis, something Walton says they see as vitally important as well.
An example of how a question can help the community while informing researchers, T1D Exchange marketing manager Sarah Tackett told DiabetesMine, works like this:
They decided to ask the question, Do you brush your teeth after you treat a low?, after a dentist with a newly diagnosed child brought it up as a suggestion. This is an issue especially around nighttime lows, when people just want to go back to sleep after treating with sugar, but worry about damage to their teeth. Parents of children with T1D tend to be particularly worried.
The responses came in fast: 85 percent of respondents said they do not brush their teeth after treating a low.
From that came a hearty, helpful, and interesting discussion among respondents on the Question of the Day page on their website. People shared feelings on the topic, and asked for advice: Phew! Im not the only one! and Is there a better way?
It can be a very special thing to see folks connecting and helping one another around the questions, Tackett said.
They dont stop there, though.
We then send [the info] on to the research team, she said, so they can consider if there is anything to dig deeper into.
So, while the data may someday be important to a study, it becomes important the moment it sparks discussion, she said.
Questions can also give respondents a sense of power and input, she said. They may ask things like What features on a pump are most important to you? to help guide inventors and manufacturers toward what people want, an empowering experience for most.
Its a great springboard, Walton agreed.
The data also does another important thing, he said: It inspires bloggers and reporters to dig into topics that the public wants to learn more about or needs to hear more about.
In other words, increased education around diabetes is a byproduct as well.
As it celebrates 10 years, the T1D Exchange and its Registry and Question of the Day are far from done, said Walton.
They continue to collect data and welcome new people into their Registry with the goal of pushing things forward.
For Panzirer, who saw a second daughter diagnosed with T1D in 2017, it must and it shall move forward. He sees the same power today as he saw back when Ball suggested this to him long ago.
We are fortunate, Panzirer said. Dana was a visionary who got this whole thing rolling. I will be forever grateful to him.
Ball, who has retired from the role since, was the right person to partner with him to make this happen, he said.
Ive been a bull in a china shop. I told Dana Im not here to make friends. Im here to bring change. Are we successful in that? No, not until we dont have to use any of these [diabetes tools] anymore. And we will keep pushing until we are there, Panzirer said.
Go here to read the rest:
A Decade of Type 1 Diabetes 'Questions of the Day': What Have We Learned? - Healthline
- Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be - Yahoo Finance - March 18th, 2024
- Doctor warns of strange telltale sign of diabetes which can appear on the legs - The Mirror - March 18th, 2024
- Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies - News-Medical.Net - March 18th, 2024
- Popular diabetes and weight loss drugs often hard to get for people who need them - NBC News - March 18th, 2024
- Your Health Matters: The ABCs of diabetes - The Globe | News, weather, sports from Worthington, Minnesota - The Globe - March 18th, 2024
- The Link Between Pancreatic Cancer and Diabetes - Cedars-Sinai - March 18th, 2024
- Nikita Kuzmin diabetes: what was he holding in the CBB house? - Cosmopolitan UK - March 18th, 2024
- FDA Approves Rezdiffra, the First Drug for Diabetes-Related Liver Disease - diaTribe Foundation - March 18th, 2024
- He took up running rather than take diabetes medication. It worked - South China Morning Post - March 18th, 2024
- Can Eating Yogurt Really Reduce Your Risk of Diabetes? - Health.com - March 18th, 2024
- Even short periods of diabetes remission are linked to lower risk of heart attack and stroke - The BMJ - March 18th, 2024
- Kidney stone risk factors and how type 2 diabetes medication may help - WECT - March 18th, 2024
- 'Making the Invisible Visible': CGMs Offer Insights for T2D - Medscape - March 18th, 2024
- Novo Nordisk Discontinues Insulin Medication After Cutting Its Price - The American Prospect - March 18th, 2024
- Infographic: Where GLP-1s Work Now -- and What's Coming - Medscape - March 18th, 2024
- Intermountain Health Experts Say Education Key to Prevention of Type 2 Diabetes | PRUnderground - PR Underground - March 18th, 2024
- International body recommends more sensitive test to indicate risk of developing diabetes - The Hindu - March 18th, 2024
- The importance of knowing your A1C level - KSAT San Antonio - March 18th, 2024
- Tandem Diabetes Care's t:slim X2 Insulin Pump is the First Automated Insulin Delivery System to Integrate with ... - Business Wire - January 9th, 2024
- Diffuse Alveolar Hemorrhage Occurring Suddenly in a Diabetic Patient With Asthma Exacerbation - Cureus - January 9th, 2024
- Virginia Tech researchers find drugs used to treat Type 2 diabetes reduce alcohol cravings - WRIC ABC 8News - January 9th, 2024
- FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss - CNN - January 9th, 2024
- Glycemic control and cardiovascular outcomes in patients with diabetes and coronary artery disease according to ... - Cardiovascular Diabetology - January 9th, 2024
- Insulin price cap: More Americans will now pay no more than $35 - USA TODAY - January 9th, 2024
- Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for cosmetic reasons instead of for diabetes and obesity - Fortune - January 9th, 2024
- No Increased Risk of Suicidal Ideation With GLP-1 Drugs - Medpage Today - January 9th, 2024
- Ask the Doctors | New research being conducted to treat diabetes - Eureka Times-Standard - January 9th, 2024
- Salivary Chloride Intracellular Channel 1 (CLIC1) as a Hub of Gene-Gene Interactome of Periodontitis With Diabetes ... - Cureus - January 9th, 2024
- Why Omada's CEO Thinks Amazon Selected His Startup as the 1st Partner for Its New Program - MedCity News - January 9th, 2024
- Researchers find drugs used to treat type 2 diabetes and obesity reduce alcohol cravings - Medical Xpress - January 9th, 2024
- Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different ... - Nature.com - January 9th, 2024
- CV Safety Profile of TheracosBio's BRENZAVVY (bexagliflozin) Confirmed in Research Published in Diabetes ... - Business Wire - January 9th, 2024
- 6 "Bad" Fruits You Should Be Eating When You Have Diabetes, According to Dietitians - EatingWell - January 9th, 2024
- Children of Women with Type 1 Diabetes Have Increased Heart Defect Risk - Inside Precision Medicine - January 9th, 2024
- Transforming Corporate Health: Fitterfly's Success in Tackling Diabetes and Weight Issues - Business Standard - January 9th, 2024
- Ozempic and weight loss | News and views - Diabetes UK - January 9th, 2024
- Drugs used to treat Type 2 diabetes reduce alcohol cravings - ScienceBlog.com - January 9th, 2024
- People taking Wegovy and Ozempic have lower risk of suicidal thoughts vs. older drugs, study finds - ABC News - January 9th, 2024
- For Those With Diabetes On Medicare Part D, Insulin Is $35...If Its Covered - Forbes - October 27th, 2023
- Biologist Douglas Melton: I was studying frogs until my son was diagnosed with diabetes then I started looking for a cure - EL PAS USA - October 27th, 2023
- Diabetes and Hearing Loss with Concept by Iowa Hearing | Paid Content - Local 5 - weareiowa.com - May 9th, 2023
- COUNTY COLUMN: Learn to Live well with diabetes at The Well - Norman Transcript - May 1st, 2023
- Want to Cut Type 2 Diabetes Risk? This High-fat Food Can Be the Answer, According to New Study - Revyuh - May 1st, 2023
- Diabetes: What It Is, Causes, Symptoms, Treatment & Types - March 13th, 2023
- A number of healthtech startups claim they can reverse Type 2 diabetes. But caveats apply, caution doctors - Economic Times - March 13th, 2023
- Tampa doctor who lost brother to diabetes calls insulin price cut a 'game changer' - ABC Action News Tampa Bay - March 5th, 2023
- New study suggest people previously infected with COVID-19 could have increased risk for diabetes - CBS Los Angeles - February 16th, 2023
- Diabetes Symptoms, Causes, & Treatment | ADA - October 15th, 2022
- A nutritionist with type 1 diabetes shares the top 5 'food swaps' she eats to manage her blood sugar - CNBC - October 15th, 2022
- Diabetes and the gut: How a bacterial protein may impact insulin - Medical News Today - October 15th, 2022
- Milton teen involved in launch of diabetes support program - Milton Daily Standard - October 15th, 2022
- Providers Now Have Free Access to Latest Diabetes Technology in One Place - PR Newswire - October 15th, 2022
- 5 Modifiable Factors in Women with History of Gestational Diabetes Mellitus That Can Reduce the Risk of T2D - Pharmacy Times - October 15th, 2022
- BCMH the stoy of Diabetes and Determination - 921News - October 15th, 2022
- Can skipping a meal lead to diabetes and fat around abdomen? - The Indian Express - October 15th, 2022
- Type 2 Diabetes Drugs Market Research Report by Drug, Application, Distribution, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 -... - October 15th, 2022
- Diabetes: Symptoms, risks, and prevention - Wilmington News Journal, OH - July 17th, 2022
- Diabetes symptoms: The sign of nerve damage that often strikes at night - severe - Express - July 17th, 2022
- Local Teen Brings Smiles and Health Kits to Kids with Diabetes - River Journal Staff - July 17th, 2022
- Type 3 diabetes: symptoms, causes and treatments - Livescience.com - July 17th, 2022
- Diabetes Travel Essentials and Tips for the Approximately 21 Million Americans that Must Manage Their Diabetes While on Vacation - PR Newswire - July 17th, 2022
- A type of 'step therapy' is an effective strategy for diabetic eye disease - National Institutes of Health (.gov) - July 17th, 2022
- Diabetes education: one in five search results for diabetes lack reliable information - Open Access Government - July 17th, 2022
- Arch City Kids Theater Troupe Fights Type 1 Diabetes With Its Annual Revue - Broadway World - July 17th, 2022
- Nutrigenomics Testing Industry Forecast to 2027 - Insights Into Obesity, Diabetes, Cancer, and Cardiovascular Disease Applications -... - July 17th, 2022
- Harvard Scientists Have Developed a Revolutionary New Treatment for Diabetes - SciTechDaily - June 16th, 2022
- Do Viruses and Coxsackievirus Cause Type 1 Diabetes? - Healthline - June 16th, 2022
- Diabetes Week: Types 1 and 2 symptoms, causes and prevention - Yahoo Entertainment - June 16th, 2022
- Diabetes And Sex: Have Safe Sex While Managing Diabetes - MadameNoire - June 16th, 2022
- Diabetes Devices Market to Expand at the CAGR of 6.4% from 2019 to 2027, Increase in Prevalence of Diabetes Expected to Drive Global Market - BioSpace - June 16th, 2022
- Anemia and Diabetes: What You Should Know - Healthline - June 16th, 2022
- Patient Knowledge of Diabetes and CKD in an Inner-City Population - DocWire News - June 16th, 2022
- ASCENSIA DIABETES CARE ANNOUNCES EUROPEAN APPROVAL OF THE NEXT-GENERATION EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM - PR Newswire - June 16th, 2022
- Understanding the Link between Diabetes Care and Sickle Cell Disease | NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases... - June 16th, 2022
- Child type 2 diabetes referrals in England and Wales jump 50% amid obesity crisis - The Guardian - June 16th, 2022
- Covenant Childrens to host diabetes camp in July - KLBK | KAMC | EverythingLubbock.com - June 16th, 2022
- Pattern of contraceptive use among reproductive-aged women with diabetes and/or hypertension: findings from Bangladesh Demographic and Health Survey -... - June 16th, 2022
- Diabetes warning: The 6 signs on your SKIN that can be a sign of life-threatening disease... - The Sun - June 16th, 2022
- www.thestreet.com - December 8th, 2021
- Long-Term Glycemic Control Cuts Risk for Severe COVID-19 With T2DM - HealthDay News - December 8th, 2021